Key facts
- LightGene’s last known valuation is $1.2M (Nov 2022).
- It has raised $13.9M; the latest was Later Stage VC in Feb 2026.
- Notable investors include GL Ventures, Beijing Bohua Capital, Chengwei Capital, Quantum Vision Electronics, Wofo Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for LightGene
- ·The full record, as it builds
Funding rounds
No funding rounds for LightGene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LightGene
Developer of intelligent spectral imaging equipment and a spectral visual analysis system designed to support disease diagnosis and enhance clinical decision-making. The company offers PMVIS spectral video imaging theory and a parallel optical path spectral video fusion algorithm to achieve high-resolution acquisition of space-spectral-time information in three dimensions, enabling clients with a path for the perception, identification, and analysis of substances.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2018
- Employees
- 25
- Website
- lightgene.com/
- Ownership
- Privately Held (backing)
LightGene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LightGene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LightGene in its N-PORT filings yet. We sweep new filings monthly.